Article
Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Nov 2011
De Pas Tommaso, Toffalorio Francesca, Manzotti Michela, Fumagalli Caterina, Spitaleri Gianluca, Catania Chiara, Delmonte Angelo, Giovannini Monica, Spaggiari Lorenzo, de Braud Filippo, Barberis Massimo
Abstract excerpt
INTRODUCTION: Mutations of the epidermal growth factor receptor (EGFR) have been proven to predict activity of the EGFR-tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib. Although the "common" EGFR mutations, such as the L858R point mutation in exon 21 and the in-frame deletional mut...
Topics
- Adenocarcinoma
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors
- Erlotinib Hydrochloride
- Female
- Gefitinib
- Humans
- Lung Neoplasms